Arcus Biosciences
RCUSRCUS · Stock Price
Historical price data
Overview
Founded in 2015, Arcus Biosciences is a clinical-stage biopharma with a mission to develop best-in-class cancer therapies through its proprietary 'Combining to Cure®' philosophy. The company has built a fully integrated platform, advancing a deep pipeline targeting key immuno-oncology pathways like adenosine signaling and TIGIT. With strategic partnerships, including a major collaboration with Gilead Sciences, and multiple programs in late-stage development, Arcus is positioned as a significant player in the next wave of oncology combination treatments.
Technology Platform
A fully integrated, biology-driven discovery engine designed to produce best-in-class small molecules and monoclonal antibodies (including Fc-silent technology) optimized for rational combination therapies in cancer.
Pipeline
30| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Casdatifan + Cabozantinib + Placebo | Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | |
| Quemliclustat + Placebo + Nab-paclitaxel + Gemcitabine | Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | |
| Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+... | Adenocarcinoma Stomach | Phase 2 | |
| Etrumadenant (AB928) + FOLFOX regimen + Zimberelimab (AB122) | Rectal Cancer | Phase 2 | |
| Zimberelimab + Domvanalimab | Melanoma | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Arcus competes with large pharma and biotech in crowded fields like PD-1 and TIGIT inhibition, but differentiates through its Fc-silent antibody design and comprehensive adenosine pathway portfolio. Its integrated 'Combining to Cure' strategy and deep Gilead partnership provide unique advantages in the race to develop next-generation immuno-oncology combinations.
Company Timeline
Founded in Hayward, United States
Series A: $107.0M
Series B: $107.0M
IPO — $120.0M